South San Francisco (March 3, 2004 ) – Hudson Health Sciences, Inc., a biopharmaceutical company headquartered in South San Francisco, California, announced today that it has elected Leon E. Rosenberg, M.D. to its Board of Directors. Dr. Rosenberg is former the head of pharmaceutical research and development for Bristol-Myers Squibb and former Dean of the Yale University School of Medicine.
“Lee Rosenberg's background and experience create an ideal fit for Hudson Health Sciences. We look forward to his guidance in helping the Company develop and bring to market innovative products to treat cancer and immunological diseases,” said Mark Ahn, Ph.D., president and CEO of Hudson Health Sciences.
“Hudson Health Sciences is engaged in innovative work with highly promising products and outstanding personnel. I am pleased to be able to provide guidance to help the Company achieve its strategic goals,” said Dr. Rosenberg. Dr. Rosenberg is currently a professor in the Department of Molecular Biology and in the Woodrow Wilson School of Public and International Affairs at Princeton University. Dr. Rosenberg also serves on the Boards of Directors of The Lovelace Respiratory Research Institute, Karo Bio, and Medicines for Malaria Venture.
About Hudson Health Sciences
Hudson Health Sciences (HHS) acquires, develops, and commercializes innovative products for the treatment of important unmet medical needs in cancer and immunological diseases. The Company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hudson Health Sciences can be found at www.hudson-health.com.
Forward Looking Safe Harbor Statement:
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.
(212) 477-9007 ext. 25